Genentech pays $35mm up front for Actelion's Tracleer
Genentech agreed to pay (uf)$35mm up front for the right to co-promote Actelion's pulmonary hypertension and chronic heart failure drug Tracleer (bosentan), in the US, upon the drug's approval for both indications.
- Intra-Biotech Deal
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.